Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

49.25 +0.14 (+0.29%)
Streaming Delayed Price Updated: 10:04 AM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,472,210
Open 49.11
Bid (Size) 49.24 (1)
Ask (Size) 49.26 (3)
Prev. Close 49.11
Today's Range 49.01 - 49.53
52wk Range 39.35 - 63.41
Shares Outstanding 2,222,113,553
Dividend Yield 4.63%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction. 
Via Benzinga
Topics Workforce
Exposures Layoff

Performance

YTD
-6.65%
-6.65%
1 Month
+19.54%
+19.54%
3 Month
+11.65%
+11.65%
6 Month
-0.38%
-0.38%
1 Year
-19.17%
-19.17%

More News

Read More
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Via Benzinga
The 3 Best Healthcare Stocks to Buy in August 2024
Via InvestorPlace
Bristol-Myers Squibb Co: Is It A Buy?
Via Talk Markets
Smart Money Is Betting Big In BMY Options
Via Benzinga
Smart Money Is Betting Big In BMY Options
Via Benzinga
3 Stocks Retirees Should Absolutely Love
Via The Motley Fool
3 Biotech Stocks With Promising Drug Pipelines: August 2024
Via InvestorPlace
Exposures Product Safety
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Via Benzinga
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Via The Motley Fool
MarketBeat Week in Review – 7/29 - 8/2
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
The 3 Biggest Earnings Beats for Q2 as of August 1, 2024
Via InvestorPlace
Topics Earnings
Exposures Financial
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
Via InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
Via InvestorPlace
The Top 3 Healthcare Stocks to Buy Now: Summer 2024
Via InvestorPlace
Post-it Manufacturer 3M Sticks Landing While Ford Tanks: Biggest Beats And Misses From Earnings Season So Far
Via Benzinga
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
Via Benzinga
Exposures COVID-19
Market Momentum: Your Weekly Financial Forecast
Via Benzinga
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Healthcare Stocks Are Coming On Strong In July Led By Biotech
Via Talk Markets
Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.